Anti-mouse VEGFR-2 RIgG1 Antibody(DC101)
Cat. No.
GM-87886MAB
Size
1mg
5mg
25mg
100mg
Quote
Data display
Description
Related products
Data display
SDS-PAGE
On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of this product is more than 95% verified by SEC-HPLC.
Description
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGFR-2
Clone DC101
Other Names 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR2, orv, sVEGFR-2
Source/Isotype Monoclonal Rat IgG1, κ
Application /
Description VEGFR-2, also known as KDR (kinase insertion domain receptor) and Flk-1 in mice, is the main receptor mediating the angiogenic response to
vascular endothelial growth factor (VEGF). DC101 is a monoclonal
antibody targeting mouse VEGFR-2, and its core mechanism is to inhibit
VEGFR-2 signaling by specifically blocking VEGF binding to VEGFR-2,
which can be used to inhibit VEGFR-2 signaling, it can inhibit tumor
angiogenesis, tumor proliferation and metastasis, and affect the activity of
cancer stem cells (CSCs) and tumor immune microenvironment.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGFR-2
Clone DC101
Other Names 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR2, orv, sVEGFR-2
Source/Isotype Monoclonal Rat IgG1, κ
Application /
Description VEGFR-2, also known as KDR (kinase insertion domain receptor) and Flk-1 in mice, is the main receptor mediating the angiogenic response to
vascular endothelial growth factor (VEGF). DC101 is a monoclonal
antibody targeting mouse VEGFR-2, and its core mechanism is to inhibit
VEGFR-2 signaling by specifically blocking VEGF binding to VEGFR-2,
which can be used to inhibit VEGFR-2 signaling, it can inhibit tumor
angiogenesis, tumor proliferation and metastasis, and affect the activity of
cancer stem cells (CSCs) and tumor immune microenvironment.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Related products
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Anti-mouse VEGFR-2 RIgG1 Antibody(DC101)
Cat. No.
GM-87886MAB
Size
1mg
5mg
25mg
100mg
Quote
Data display
Description
Related products
Data display
SDS-PAGE
On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of this product is more than 95% verified by SEC-HPLC.
Description
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGFR-2
Clone DC101
Other Names 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR2, orv, sVEGFR-2
Source/Isotype Monoclonal Rat IgG1, κ
Application /
Description VEGFR-2, also known as KDR (kinase insertion domain receptor) and Flk-1 in mice, is the main receptor mediating the angiogenic response to
vascular endothelial growth factor (VEGF). DC101 is a monoclonal
antibody targeting mouse VEGFR-2, and its core mechanism is to inhibit
VEGFR-2 signaling by specifically blocking VEGF binding to VEGFR-2,
which can be used to inhibit VEGFR-2 signaling, it can inhibit tumor
angiogenesis, tumor proliferation and metastasis, and affect the activity of
cancer stem cells (CSCs) and tumor immune microenvironment.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGFR-2
Clone DC101
Other Names 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR2, orv, sVEGFR-2
Source/Isotype Monoclonal Rat IgG1, κ
Application /
Description VEGFR-2, also known as KDR (kinase insertion domain receptor) and Flk-1 in mice, is the main receptor mediating the angiogenic response to
vascular endothelial growth factor (VEGF). DC101 is a monoclonal
antibody targeting mouse VEGFR-2, and its core mechanism is to inhibit
VEGFR-2 signaling by specifically blocking VEGF binding to VEGFR-2,
which can be used to inhibit VEGFR-2 signaling, it can inhibit tumor
angiogenesis, tumor proliferation and metastasis, and affect the activity of
cancer stem cells (CSCs) and tumor immune microenvironment.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Related products
Message consultation
reset
submit
Message
Message consultation
reset
submit